U.S. Kidney Stones Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Kidney Stones Market
- ✓Market Size 2024: USD 2.1 billion
- ✓Market Size 2032: USD 3.0 billion
- ✓CAGR: 4.6%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock Multi-Year Contracts: Hospital procurement teams and ASC operators should negotiate multi-year single-use ureteroscope contracts before the CY2026 OPPS rule takes effect on January 1, 2026, because reimbursement shifts will compress per-procedure margins across facility types.
U.S. Kidney Stone Care: Market Overview
The U.S. kidney stones market, spanning ureteroscopy, shockwave lithotripsy, percutaneous nephrolithotomy, and prescription prevention therapy, was valued at USD 2.1 billion in 2024. NIDDK data indicate that roughly one in eleven Americans will develop a kidney stone, and the Centers for Disease Control and Prevention links rising incidence to obesity and type 2 diabetes. Demand is therefore anchored in a large, recurring patient base rather than discretionary elective surgery, which gives reimbursement policy outsized influence over market value.
Market structure reflects a hybrid model in which government sets the economics and private firms drive the technology. The Centers for Medicare and Medicaid Services (CMS) publishes annual Physician Fee Schedule values and Hospital Outpatient Prospective Payment System rates that determine procedure profitability for urology practices and hospitals. Private manufacturers, led by Boston Scientific, Olympus Corporation of the Americas, and Karl Storz Endoscopy America, have driven innovation in single-use ureteroscopes and access sheaths, while government dominates only pricing and coverage decisions.
Policy-Driven Growth in U.S. Kidney Stone Care
The Inflation Reduction Act of 2022 (Public Law 117-169) is the most consequential demand driver for prevention therapy. Its Medicare Part D redesign caps annual beneficiary out-of-pocket spending at USD 2,000 from 2025, removing the cost barrier that previously interrupted long-term potassium citrate and thiazide regimens. Because recurrence affects roughly half of patients within ten years of a first episode, sustained adherence converts episodic procedure demand into recurring prescription volume across the Medicare population.
CMS coverage rules create the second and third mechanisms. The CMS Ambulatory Surgical Center Covered Procedures List determines which urolithiasis procedures ASCs can bill under Medicare, and each annual update moves ureteroscopy volume from hospital outpatient departments into lower-cost settings. Separately, CPT 52356, which describes ureteroscopy with lithotripsy, and CPT 50590 for extracorporeal shockwave lithotripsy are valued through the annual Physician Fee Schedule, so each revaluation directly alters procedure throughput and capital equipment purchasing decisions.
Regulatory Barriers and Compliance Costs
The FDA's Center for Devices and Radiological Health (CDRH) administers premarket review for urological devices. Ureteroscopes and access sheaths typically follow the 510(k) pathway under 21 CFR Part 807, with a MDUFA performance goal of 90 FDA days for decisions, while shockwave lithotripters require premarket approval under 21 CFR Part 814 with a 180-day review goal. From February 2, 2026, the Quality Management System Regulation under 21 CFR Part 820 aligns manufacturers with ISO 13485, adding documentation and audit costs for every device line.
Market access also depends on price transparency and state licensing. Hospitals must publish standard charges under the Hospital Price Transparency requirements in 45 CFR Part 180, administered by CMS, and face civil monetary penalties for noncompliance. States including New York and North Carolina administer certificate of need programmes that require state health department approval before an ASC adds lithotripsy or ureteroscopy capacity, adding delays commonly measured in months.
Policy-Created Opportunities in the United States
The Part D out-of-pocket cap creates an opportunity for pharmacy-led adherence programmes targeting generic potassium citrate and thiazide prophylaxis. Under the Medicare Prescription Payment Plan, enrolled beneficiaries spread out-of-pocket costs across monthly payments, and pharmacy benefit managers and specialty urology networks can capture this demand by enrolling recurrent stone formers in structured follow-up programmes. Mission Pharmacal and Viatris are positioned to supply high-volume potassium citrate and generic formulations to these programmes.
The CMS ASC Covered Procedures List creates a second opportunity for freestanding surgical centers to acquire single-use ureteroscopy and lithotripsy capacity. Operators that secure ASC-certified facilities before the CY2026 OPPS rule takes effect on January 1, 2026 gain payment-rate stability relative to hospital outpatient departments. Meanwhile, HRSA's 340B Drug Pricing Program allows qualifying safety-net and urology hospitals to purchase prevention drugs at discounted prices, creating procurement opportunities for generic distributors serving covered entities.
Regulatory and Policy Environment
The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), which defines device classification and premarket pathways, and Title XVIII of the Social Security Act, which governs Medicare payment for urological services. The Inflation Reduction Act of 2022 (Public Law 117-169) layers drug pricing and Part D benefit redesign onto this framework. Responsible agencies are the FDA's CDRH for devices, CMS for reimbursement and price transparency, and HRSA for 340B administration, with key compliance requirements including 510(k) or PMA clearance, QMSR conformity from February 2, 2026, and Hospital Price Transparency postings under 45 CFR Part 180.
Upcoming changes include the CY2026 OPPS final rule effective January 1, 2026, the MDUFA V reauthorization process ahead of the program's September 30, 2027 expiry, and annual indexing of the USD 2,000 Part D cap. Compared with regional peers, the U.S. framework offers faster device clearance than the EU Medical Device Regulation (Regulation (EU) 2017/745), which requires notified body certification for Class IIa devices, while Canada's Medical Devices Regulations (SOR/98-282) run through Health Canada with provincially funded procedures under the Canada Health Act. Reimbursement remains more fragmented in the U.S. than in either peer.
Long-Term Policy Outlook for U.S. Kidney Stone Care
By 2032, the most significant policy shift will be the migration of urological procedures toward site-neutral payment structures. CMS has proposed site-neutral policies for selected outpatient services, and each successive OPPS rulemaking narrows the reimbursement gap between hospital outpatient departments and freestanding ASCs. This will compress hospital margins on ureteroscopy and redirect capital investment toward ASCs and office-based lithotripsy units.
Drug pricing reform will extend beyond the first Medicare negotiated drugs as the Inflation Reduction Act's negotiation programme phases in Part B drugs from 2028, reshaping the economics of injectable therapies used in complicated stone management. Generic potassium citrate and thiazides will remain outside negotiation pressure, preserving volume for generic manufacturers through 2032. FDA cybersecurity expectations under Section 524B of the Federal Food, Drug, and Cosmetic Act will add compliance cost to connected ureteroscopes and lithotripters.
Frequently Asked Questions
Market Segmentation
- Ureteroscopy
- Shockwave Lithotripsy
- Percutaneous Nephrolithotomy
- Medical Expulsive Therapy
- Pharmacological Prophylaxis
- Hospitals
- Ambulatory Surgical Centers
- Office-Based Urology Practices
- Diagnostic Imaging Centers
- Medicare
- Medicaid
- Commercial Insurance
- Self-Pay Patients
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.